We are live on ! Find out more
WINT

Windtree Therapeutics
WINT

Delisted

WINT was delisted on the 20th of August, 2025.

Back to rankings

1 hedge funds and large institutions have $4.87K invested in Windtree Therapeutics in 2024 Q2 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 0 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% less ownership

Funds ownership: 0.01% → 0.01% (-0%)

75% less funds holding

Funds holding: 4 → 1 (-3)

75% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 4

98% less capital invested

Capital invested by funds: $239K → $4.87K (-$234K)

Holders
1
Holders Change
-3
Holders Change %
-75%
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
+$7.04K

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$215K
2
Vanguard Group
Vanguard Group
Pennsylvania
-$14.7K
3
Geode Capital Management
Geode Capital Management
Massachusetts
-$4.95K
4
Citadel Advisors
Citadel Advisors
Florida
-$3.77K
5
Wells Fargo
Wells Fargo
California
-$15

WINT Hedge Fund Activity: Q2 2024 in Review

1 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Windtree Therapeutics (WINT) for Q2 2024, worth a combined $4.87K — down 98% from $239K a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of WINT and 1 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 0 added.

The largest buyer was Tower Research Capital (TRC), opening a new position worth an estimated $7.04K. The largest seller was Deerfield Management, exiting entirely with an estimated $215K sold.

  • 1 institutional investor held Windtree Therapeutics (WINT) as of Q2 2024, down from 4 in Q1 2024.
  • Funds reported $4.87K of Windtree Therapeutics stock for Q2 2024, down 98% quarter-over-quarter.
  • 1 fund opened new Windtree Therapeutics positions in Q2 2024 and 4 closed out, a net change of -3 holders.
  • The largest Windtree Therapeutics buyer in Q2 2024 was Tower Research Capital (TRC), an estimated $7.04K added.
  • The largest Windtree Therapeutics seller in Q2 2024 was Deerfield Management, an estimated $215K sold.

Based on aggregated 13F filings for Q2 2024.